patients with osteosarcoma treated with neoadjuvant chemotherapy was uncertain, 14) they have been still used to obtain information on tumor size, appearance, margin, cortical destruction and periosteal reaction before and after chemotherapy.
PET/CT scan can more correctly identify viable residual tumor and detect changes in tissue metabolism that generally precede the structural changes, thus it should be more accurate for assessing therapeutic response. 15) Since Jones et al. documented 18 F-FDG PET data of nine patients including three osteosarcoma patients who had neoadjuvant chemotherapy, 12) several studies have demonstrated that 18 F-FDG PET is useful for noninvasive evaluation of response to neoadjuvant chemotherapy in osteosarcoma. 16, 17) A meta-analysis recently suggested cut-off values of standardized uptake and its reduction rate for predicting the histological response to chemotherapy. However, parameters of PET/CT can be influenced by various factors and it may not be easy to generalize cut-off values to predict response to chemotherapy.
We, therefore, evaluated the effectiveness of imaging studies of conventional radiographs and PET/CT in assessment of neoadjuvant chemotherapy effect for osteosarcoma and tried to establish a general principle in interpretation of PET/CT parameters.
Materials and Methods

Patients and study designs
From January 2010 to July 2013, 18 patients with histologically confirmed high-grade osteosarcoma were retrospectively enrolled. All patients had undergone an open biopsy, pre-chemotherapy plain radiographs and a pre-chemotherapy PET/CT scan before neoadjuvant chemotherapy was initiated. Patients received consistently two cycles of neoadjuvant chemotherapy, which consisted of different combinations of high-dose methotrexate, doxorubicin, ifosfamide, and dacarbazine. Each cycle of neoadjuvant chemotherapy took at least three weeks. They then had post-chemotherapy plain radiographs and a post-chemotherapy PET/CT scan before definitive surgery. The pre-chemotherapy PET/CT scans were performed within median one week (range, 0-2 weeks) before the initiation of neoadjuvant chemotherapy, and the post-chemotherapy PET/CT scans were performed within median one week (range, 0-2 weeks) after the end of chemotherapy. The resected tumor specimens were pathologically examined to estimate histological response grade using a conventional mapping method as described in previous literatures. 18, 19) Our institutional review board approved this study.
Categorization of ragiographic findings
'Good' radiographic response was defined as radiographic findings such as marked decrease in tumor size, or increased ossification, definite margination and prominent periosteal new bone formation without increase in size. Other findings were categorized into 'not good' radiographic response.
18 F-FDG PET/CT
All patients fasted for at least six hours before the 18 
Pathological assessment
After surgery, excised specimens were cut longitudinally in the plane deemed most likely to reveal residual viable tumor, and tumor necrosis fractions were then defined as the percentage of devitalized parts of the tumor in the examined planes. Pathological good responders (GRs) and poor responders (PRs) were differentiated. Necrosis fraction ≥90% and ＜90% were considered as good response and poor response respectively. (Fig. 1 ).
Statistical analysis
Discussion
Conventional diagnostic imaging modalities were performed to assess neoadjuvant chemotherapy effect, such as radiography, CT, MRI, and bone scintigraphy. However, a study 23) reported that category of radiographic findings was not correlated to histological response grade at all. In addition, the reduction in tumor size assessed by conventional modalities was less correlated with histological response in previous studies. 8, 9, 11, 13) Some preveious studies suggested that other findings such as changes in T2 signal on MRI and in radioisotope uptake on bone scintigraphy were not reliable, either. 9, 10) A meta-analysis suggested that post-chemotherapy SUVmax ≤ 2.5 and reduction rate of SUVmax ≥50% are valuable predictors to assess the chemotherapy-induced tumor necrosis. 17) SUVmax in a single pixel which represents the most aggressive portion is most widely used for determining tumor SUV, however, less sensitive to tumor shape, size, and location of the region of interest (ROI). [24] [25] [26] Although we identified that reduction rate of SUVmax was cor- report different measurements or criteria to discriminate good histological response as in previous studies from different centers. 6, 8, 27) Although the extremely rare incidence of only a few osteosarcoma cases per million person-years on a worldwide basis 28) makes data collection difficult, different centers have to make an effort to create their own standard of judgement and carefully accept the results of previous studies under consideration of different factors.
This current study had several limitations. It was a retrospective study and we enrolled young and old patients together in this study.
The number of patients was too small, therefore, differences in evaluation parameters according to histological response to neoadjuvant chemotherapy were simply compared. In addition, we did not investigate other imaging studies such as CT, MRI and bone scintigraphy.
While radiographic finding category was not reliable to assess neoadjuvant chemotherapy effect for osteosarcoma, reduction rate of SUVmax was a useful indicator in this study. As parameters of PET/ CT can be influenced by various factors of settings, different centers need their own standard of judgement with reference of previous studies. 
